Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients

British Journal of Cancer

Volumn 108, Issue 4, 2013, Pages 901-907

  Pichler, M ^a   Hutterer, G C ^a   Stoeckigt, C ^a   Chromecki, T F ^a   Stojakovic, T ^a   Golbeck, S ^a   Eberhard, K ^a   Gerger, A ^a   Mannweiler, S ^a   Pummer, K ^a   Zigeuner, R ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

prognosis; renal cell carcinoma; validation study

Indexed keywords

ADULT; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CAUSE OF DEATH; FEMALE; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; NEUTROPHIL COUNT; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PREMEDICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TUMOR VOLUME;

AGED; BLOOD CELL COUNT; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; LYMPHOCYTES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUTROPHILS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84875221335     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.28     Document Type: Article

References (43)

1. Akpek M, Kaya MG, Lam YY, Sahin O, Elcik D, Celik T, Ergin A, Gibson CM (2012) Relation of neutrophil/lymphocyte ratio to coronary flow to inhospital major adverse cardiac events in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol 110(5): 621-627.
2. Al-Ali BM, Ress AL, Gerger A, Pichler M (2012) MicroRNAs in renal cell carcinoma: implications for pathogenesis, diagnosis, prognosis and therapy. Anticancer Res 32(9): 3727-3732.
3. Alkhouri N, Morris-Stiff G, Campbell C, Lopez R, Tamimi TA, Yerian L, Zein NN, Feldstein AE (2012) Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. Liver Int 32(2): 297-302.
4. Altman DG, Royston P (2000) What do we mean by validating a prognostic model? Stat Med 19(4): 453-473.
5. Atzpodien J, Royston P, Wandert T, Reitz M (2003) Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 88(3): 348-353.
6. Azab B, Jaglall N, Atallah JP, Lamet A, Raja-Surya V, Farah B, Lesser M, Widmann WD (2011) Neutrophil-lymphocyte ratio as a predictor of adverse outcomes of acute pancreatitis. Pancreatology 11(4): 445-452.
7. Bleeker SE, Moll HA, Steyerberg EW, Donders AR, Derksen-Lubsen G, Grobbee DE, Moons KG (2003) External validation is necessary in prediction research: a clinical example. J Clin Epidemiol 56(9): 826-832.
8. Crispen PL, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED (2008) Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer 113(3): 450-460.
9. Donskov F, von der Maase H (2006) Impact of immune parameters on longterm survival in metastatic renal cell carcinoma. J Clin Oncol 24(13): 1997-2005.
10. Ficarra V, Brunelli M, Cheng L, Kirkali Z, Lopez-Beltran A, Martignoni G, Montironi R, Novara G, Van Poppel H (2010) Prognostic and therapeutic impact of the histopathologic definition of parenchymal epithelial renal tumors. Eur Urol 58(5): 655-668.
11. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366(10): 883-892.
12. Gibson PH, Croal BL, Cuthbertson BH, Small GR, Ifezulike AI, Gibson G, Jeffrey RR, Buchan KG, El-Shafei H, Hillis GS (2007) Preoperative neutrophil-lymphocyte ratio and outcome from coronary artery bypass grafting. Am Heart J 154(5): 995-1002.
13. Harrell Jr. FE, Califf RM, Pryor DB, Lee KL, Rosati RA (1982) Evaluating the yield of medical tests. JAMA 247(18): 2543-2546.
14. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27(34): 5794-5799.
15. Hotta K, Sho M, Fujimoto K, Shimada K, Yamato I, Anai S, Konishi N, Hirao Y, Nonomura K, Nakajima Y (2011) Prognostic significance of CD45RO memory T cells in renal cell carcinoma. Br J Cancer 105(8): 1191-1196.
16. Imtiaz F, Shafique K, Mirza SS, Ayoob Z, Vart P, Rao S (2012) Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population. Int Arch Med 5(1): 2
17. Jagdev SP, Gregory W, Vasudev NS, Harnden P, Sim S, Thompson D, Cartledge J, Selby PJ, Banks RE (2010) Improving the accuracy of preoperative survival prediction in renal cell carcinoma with C-reactive protein. Br J Cancer 103(11): 1649-1656.
18. Jensen HK, Donskov F, Marcussen N, Nordsmark M, Lundbeck F, von der Maase H (2009) Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol 27(28): 4709-4717.
19. Jeron A, Pfoertner S, Bruder D, Geffers R, Hammerer P, Hofmann R, Buer J, Schrader AJ (2009) Frequency and gene expression profile of regulatory T cells in renal cell carcinoma. Tumour Biol 30(3): 160-170.
20. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P (2001) A postoperative prognostic nomogram for renal cell carcinoma. J Urol 166(1): 63-67.
21. Keizman D, Ish-Shalom M, Huang P, Eisenberger MA, Pili R, Hammers H, Carducci MA (2012) The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer 48(2): 202-208.
22. Kocyigit I, Eroglu E, Unal A, Sipahioglu MH, Tokgoz B, Oymak O, Utas C (2012) Role of neutrophil/lymphocyte ratio in prediction of disease progression in patients with stage-4 chronic kidney disease. J Nephrol; e-pub ahead of print 8 May 2012; doi:10.5301/jn.5000152
23. Kondo T, Ito F, Nakazawa H, Horita S, Osaka Y, Toma H (2004) High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma. J Urol 171(6 Pt 1): 2171-2175.
24. Lam JS, Klatte T, Kim HL, Patard JJ, Breda A, Zisman A, Pantuck AJ, Figlin RA (2008) Prognostic factors and selection for clinical studies of patients with kidney cancer. Critical Rev Oncol/Hematol 65(3): 235-262.
25. Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS, Zincke H (2003) Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 97(7): 1663-1671.
26. Liotta F, Gacci M, Frosali F, Querci V, Vittori G, Lapini A, Santarlasci V, Serni S, Cosmi L, Maggi L, Angeli R, Mazzinghi B, Romagnani P, Maggi E, Carini M, Romagnani S, Annunziato F (2011) Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma. BJU Int 107(9): 1500-1506.
27. Meskawi M, Sun M, Trinh QD, Bianchi M, Hansen J, Tian Z, Rink M, Ismail S, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI (2012) A review of integrated staging systems for renal cell carcinoma. Eur Urol 62(2): 303-314.
28. Novara G, Ficarra V, Antonelli A, Artibani W, Bertini R, Carini M, Cosciani Cunico S, Imbimbo C, Longo N, Martignoni G, Martorana G, Minervini A, Mirone V, Montorsi F, Schiavina R, Simeone C, Serni S, Simonato A, Siracusano S, Volpe A, Carmignani G (2010) Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? Eur Urol 58(4): 588-595.
29. Ohno Y, Nakashima J, Ohori M, Hatano T, Tachibana M (2010) Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J Urol 184(3): 873-878.
30. Pedersen BK, Bruunsgaard H, Jensen M, Krzywkowski K, Ostrowski K (1999) Exercise and immune function: effect of ageing and nutrition. Proc Nutr Soc 58(3): 733-742.
31. Pichler M, Hutterer GC, Chromecki TF, Jesche J, Kampel-Kettner K, Pummer K, Zigeuner R (2012) Renal cell carcinoma stage migration in a single European centre over 25 years: effects on 5-and 10-year metastasisfree survival. Int Urol Nephrol 44(4): 997-1004.
32. Pichler M, Hutterer GC, Chromecki TF, Jesche J, Kampel-Kettner K, Rehak P, Pummer K, Zigeuner R (2011) External validation of the Leibovich prognosis score for nonmetastatic clear cell renal cell carcinoma at a single European center applying routine pathology. J Urol 186(5): 1773-1777.
33. Ramsey S, Lamb GW, Aitchison M, McMillan DC (2008) Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer. BJU Int 101(8): 959-963.
34. Roxburgh CS, McMillan DC (2010) Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 6(1): 149-163.
35. Siddiqui SA, Frigola X, Bonne-Annee S, Mercader M, Kuntz SM, Krambeck AE, Sengupta S, Dong H, Cheville JC, Lohse CM, Krco CJ, Webster WS, Leibovich BC, Blute ML, Knutson KL, Kwon ED (2007) Tumor-infiltrating Foxp3-CD4CD25 T cells predict poor survival in renal cell carcinoma. Clin Cancer Res 13(7): 2075-2081.
36. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1): 10-29.
37. Sun M, Bianchi M, Hansen J, Trinh QD, Abdollah F, Tian Z, Sammon J, Shariat SF, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI (2012) Chronic kidney disease after nephrectomy in patients with small renal masses: a retrospective observational analysis. Eur Urol 62(4): 696-703.
38. Sun M, Shariat SF, Cheng C, Ficarra V, Murai M, Oudard S, Pantuck AJ, Zigeuner R, Karakiewicz PI (2011) Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol 60(4): 644-661.
39. Tamhane UU, Aneja S, Montgomery D, Rogers EK, Eagle KA, Gurm HS (2008) Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol 102(6): 653-657.
40. Terradas R, Grau S, Blanch J, Riu M, Saballs P, Castells X, Horcajada JP, Knobel H (2012) Eosinophil count and neutrophil-lymphocyte count ratio as prognostic markers in patients with bacteremia: a retrospective cohort study. PloS one 7(8): e42860
41. Tsai JC, Sheu SH, Chiu HC, Chung FM, Chang DM, Chen MP, Shin SJ, Lee YJ (2007) Association of peripheral total and differential leukocyte counts with metabolic syndrome and risk of ischemic cardiovascular diseases in patients with type 2 diabetes mellitus. Diabetes/Metabol Res Rev 23(2): 111-118.
42. Zahorec R (2001) Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 102(1): 5-14.
43. Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS (2001) Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 19(6): 1649-1657.